Blog

Full Release: iFyber Expands Analytical Capabilities with Launch of Advanced LC-MS Services iFyber, LLC, a global preclinical contract research organization (CRO), has announced the expansion of its advanced Liquid Chromatography–Mass Spectrometry (LC-MS) services through the addition of a leading-edge equipment platform and two senior technical experts. These additions expand iFyber’s analytical portfolio and further its…

Liquid chromatography–mass spectrometry (LC-MS) is a cornerstone of biomedical research, drug development, and clinical diagnostics. Immunoaffinity mass spectrometry (IA-MS) enhances LC-MS by combining immunoaffinity enrichment with its high sensitivity and selectivity, overcoming challenges posed by complex biological matrices. IA-MS is a powerful method for biomarker quantification, complementing traditional ligand-binding assays (LBAs). Gary Schultz, PhD, Director…

Slow-healing wounds, like diabetic foot ulcers, venous leg wounds, and pressure ulcers, frequently turn into long-term battles. When dealing with chronic wounds, treatment can be difficult to target due to a multitude of complicating factors. Diabetes, vascular disease, and immune suppression all reduce the body’s ability to fight infection and repair tissue. Additionally, microbes within…

In a landmark shift that blends scientific progress with environmental responsibility, the United States Pharmacopeia (USP) has endorsed the use of non-animal-derived reagents for endotoxin testing. This decision marks a pivotal advancement in pharmaceutical safety testing while paving the way for a more ethical and sustainable industry standard. For decades, the pharmaceutical and medical device sectors have relied on…